标题
The multiple myelomas — current concepts in cytogenetic classification and therapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 15, Issue 7, Pages 409-421
出版商
Springer Nature
发表日期
2018-04-23
DOI
10.1038/s41571-018-0018-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
- (2017) Wilson I. Gonsalves et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- (2017) Sharmilan Thanendrarajan et al. HAEMATOLOGICA
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
- (2017) Cristina Jiménez et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
- (2017) S K Kumar et al. LEUKEMIA
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Natural history of t(11;14) multiple myeloma
- (2017) A Lakshman et al. LEUKEMIA
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
- (2017) Gunjan L. Shah et al. LEUKEMIA & LYMPHOMA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- (2017) L. Rasche et al. Nature Communications
- Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
- (2017) N Tandon et al. Blood Cancer Journal
- Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
- (2017) M Chin et al. Blood Cancer Journal
- Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
- (2017) M Binder et al. Blood Cancer Journal
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- (2017) Sharmilan Thanendrarajan et al. HAEMATOLOGICA
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
- (2017) Cyrille Touzeau et al. HAEMATOLOGICA
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Diagnosis and Management of Waldenström Macroglobulinemia
- (2017) Prashant Kapoor et al. JAMA Oncology
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
- (2016) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
- (2016) Amro M. S. El-Ghammaz et al. ANNALS OF HEMATOLOGY
- How I treat acute myeloid leukemia presenting with preexisting comorbidities
- (2016) Y. Ofran et al. BLOOD
- Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
- (2016) M. S. Raab et al. BLOOD
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
- (2016) N Majithia et al. LEUKEMIA
- Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
- (2016) W I Gonsalves et al. LEUKEMIA
- Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
- (2016) K M Kortuem et al. Blood Cancer Journal
- Outcomes of primary refractory multiple myeloma and the impact of novel therapies
- (2015) Neil Majithia et al. AMERICAN JOURNAL OF HEMATOLOGY
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
- (2015) B. Hebraud et al. BLOOD
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- (2015) J. R. Sawyer et al. BLOOD
- Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
- (2015) R. Kuiper et al. BLOOD
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
- (2015) M.-L. Chretien et al. BLOOD
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene signature combinations improve prognostic stratification of multiple myeloma patients
- (2015) W J Chng et al. LEUKEMIA
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- (2014) J. R. Sawyer et al. BLOOD
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease
- (2014) Klaus M. Kortüm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death
- (2014) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- (2013) Koji Sasaki et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Peripheral smear clues for Bordetella pertussis
- (2013) S. Pandey et al. BLOOD
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
- (2013) Kai Neben et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
- (2013) A J Greenberg et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Genomic analysis of high-risk smoldering multiple myeloma
- (2012) L. Lopez-Corral et al. HAEMATOLOGICA
- Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
- (2012) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
- (2012) J A Katzmann et al. LEUKEMIA
- A gene expression signature for high-risk multiple myeloma
- (2012) R Kuiper et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
- (2010) H. Avet-Loiseau et al. BLOOD
- A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
- (2010) C. M. Annunziata et al. BLOOD
- Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
- (2010) K. Neben et al. HAEMATOLOGICA
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
- (2010) L. Lode et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
- (2009) Pavel Nemec et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started